Fenwick Represents Maze Therapeutics in $150M Underwritten Offering

Fenwick represented Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, in its underwritten registered offering of an aggregate of 6,390,000 shares of its common stock and pre-funded warrants, at a price of $23.50 per share. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are approximately $150 million. More information can be obtained from Maze Therapeutic’s announcement.

The Fenwick transaction team included corporate partners Amanda Rose and Chelsea Anderson and associates Marianna Zabkowski, Nikki Williams, Sarah Marshall and Nisha Porchezhiyan.